Tag: Alzheimer’s
Gut Microbial Taxonomic Profiles Differ With, Without Preclinical Alzheimer Disease
Change in gut microbiome composition associated with β-amyloid and tau pathological brain biomarkers
Bladder Cancer Treatment May Lower Risk for Alzheimer and Related Dementias
Greater effect seen for patients aged 70 years and older at time of bacillus Calmette-Guerin vaccination
Medicare Will Cover New Class of Alzheimer Drugs if Fully Approved by FDA, With...
Drug makers will also have to gather and keep data in a registry showing how the drugs are working in the real world
Causal Link ID’d for Alzheimer Disease, Generalized Epilepsy
Genetic predisposition to Alzheimer's also linked to increased risk of focal epilepsy with hippocampal sclerosis
Allopurinol May Cut Risk for Neurodegenerative Diseases
Allopurinol linked to 13 to 34 percent lower risk for Parkinson disease, Alzheimer disease, ALS
Medicare Spending Would Increase $2.0 to $5.1 Billion With Lecanemab
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636
Genetic Links Seen for HDL Cholesterol, Systolic BP With Alzheimer Disease
Genetically determined high-density lipoprotein cholesterol and systolic blood pressure linked to increased odds of Alzheimer disease
FDA Approves First Drug Meant to Ease Alzheimer Disease-Linked Agitation
Patients who received 2 or 3 mg of Rexulti had significant improvements in agitation scores compared with patients taking a placebo
Experimental Drug for Alzheimer Disease Slows Decline in Thinking
Eli Lilly says drug slows memory and thinking declines in early symptomatic Alzheimer disease patients by more than a third
Suvorexant Cuts Tau Phosphorylation and Amyloid-β Concentrations
Proof-of-concept study is 'encouraging' for repurposing insomnia drug, authors say
